Merck & CompanyvsPraxis Precision Medicines

MRK and PRAX stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

PRAX

Praxis Precision Medicines, Inc.

$300.43

Value $8.4B

-3.37%
PRAX's page

Merck & Company (MRK) has a market value of $331B and Praxis Precision Medicines (PRAX) $8.4B. Over the last year, with dividends, MRK moved +44.8% and PRAX +58.7%. Dividend yield: MRK 2.54%, PRAX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$331B

    PRAX$8.4B

    MRK is 40 times PRAX

  • Revenue, 12 months

    MRK$67.4B

    PRAX$0

  • Net income, 12 months

    MRK$2.5B

    PRAX-$359M

  • Operating margin

    MRK–

    PRAX–

  • ROIC

    MRK3.9%

    PRAX-30.7%

    34.6 points apart

  • P/E

    MRK134.8

    PRAX–

  • Dividend yield

    MRK2.5%

    PRAX0.0%

    2.5 points apart

  • 5-year return

    MRK+93.0%

    PRAX+7.3%

    85.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+93.0%

PRAX+7.3%

010020020222023202420252026
Returns by period
PeriodMRKWith dividendsPRAXWith dividends
1 year since November 19, 2025+44.8%Price +40.7%+58.7%Price +58.7%
3 years since November 20, 2023+42.7%+12.6% a yearPrice +30.2%+1,528.3%+153.5% a yearPrice +1,528.3%
5 years since November 19, 2021+93.0%+14.1% a yearPrice +65.7%+7.3%+1.4% a yearPrice +7.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyPRAXPraxis Precision Medicines

Valuation

MRKPRAX
Valuation
Price$133.72$300.43
Market value$331B$8.4B
Enterprise value (EV)$375B$7.1B
P/E134.8–
P/E, 5-year median14.8–
P/B7.46.6
EV/EBIT78.7–
Free cash flow yield4.5%–

Results and growth

MRKPRAX
Results and growth
Revenue, 12 months$67.4B$0
Net income, 12 months$2.5B-$359M
Free cash flow, 12 months$14.7B-$324M
Earnings per share, 12 months$0.98-$12.81
Revenue growth, year on year1.3%-100.0%
Revenue growth a year, past+9.4%over 5 years–
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKPRAX
Margins and returns on capital
Gross margin71.8%–
Operating margin––
Net margin3.6%–
ROIC3.9%-30.7%
ROE5.2%-34.4%

Balance sheet

MRKPRAX
Balance sheet
Cash$9.7B$1.3B
Total debt$53.8B$732.0K
Net debt / EBITDA5.7–
Interest cover2.4×–

Dividends and buybacks

MRKPRAX
Dividends and buybacks
Dividend yield2.5%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.5%–
Shareholder yield4.1%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or PRAX

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Praxis Precision Medicines?

By market value, Merck & Company ($331B) is about 39.5 times Praxis Precision Medicines ($8.4B), at today's prices.

How did MRK and PRAX stock do over the last 5 years?

Since November 19, 2021, MRK's price moved +65.7% and PRAX's +7.3%. With dividends: MRK +93.0% (+14.1% a year), PRAX +7.3% (+1.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or PRAX?

The dividend yield at today's price is 2.54% for Merck & Company and none for Praxis Precision Medicines. Over the last twelve months they paid $3.40 and – per share.

Which is the better investment, Merck & Company or Praxis Precision Medicines?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.